Clinical Trials · NCT06596135

Open-Label Extension Study of Setmelanotide

Name: Open-Label Extension Study of Setmelanotide
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Enrolling By InvitationPhase 3Setmelanotide

Phase: Phase 3
Recruitment status: Enrolling By Invitation
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 30
Start date: Oct 2024
Locations: 13 sites, United States
Primary endpoint: Safety and tolerability of setmelanotide assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

View Setmelanotide compound reference